| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 29 | 2025 | 218 | 7.570 |
Why?
|
| Vaccination | 49 | 2025 | 655 | 6.430 |
Why?
|
| Immunization Schedule | 15 | 2025 | 122 | 3.930 |
Why?
|
| Drug Overdose | 9 | 2023 | 57 | 3.170 |
Why?
|
| Infant | 51 | 2025 | 1192 | 2.890 |
Why?
|
| Influenza Vaccines | 21 | 2024 | 273 | 2.890 |
Why?
|
| Opioid-Related Disorders | 6 | 2023 | 172 | 2.550 |
Why?
|
| Analgesics, Opioid | 11 | 2023 | 246 | 2.440 |
Why?
|
| Humans | 122 | 2025 | 17762 | 2.440 |
Why?
|
| Social Media | 4 | 2021 | 12 | 2.430 |
Why?
|
| Parents | 10 | 2021 | 296 | 2.340 |
Why?
|
| Child, Preschool | 46 | 2025 | 1419 | 2.250 |
Why?
|
| Influenza, Human | 14 | 2024 | 265 | 1.920 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2024 | 390 | 1.750 |
Why?
|
| Female | 76 | 2025 | 12740 | 1.650 |
Why?
|
| Health Knowledge, Attitudes, Practice | 12 | 2021 | 382 | 1.630 |
Why?
|
| Male | 64 | 2025 | 10106 | 1.590 |
Why?
|
| Vaccines, Inactivated | 9 | 2020 | 67 | 1.440 |
Why?
|
| Child | 37 | 2022 | 2491 | 1.400 |
Why?
|
| United States | 45 | 2025 | 4003 | 1.350 |
Why?
|
| Aluminum | 3 | 2022 | 14 | 1.340 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2021 | 121 | 1.320 |
Why?
|
| Cohort Studies | 30 | 2024 | 2586 | 1.300 |
Why?
|
| Retrospective Studies | 28 | 2024 | 2461 | 1.290 |
Why?
|
| Internet | 4 | 2020 | 231 | 1.280 |
Why?
|
| Pregnancy Complications, Infectious | 7 | 2024 | 146 | 1.260 |
Why?
|
| Consumer Health Information | 3 | 2020 | 14 | 1.240 |
Why?
|
| Mothers | 2 | 2020 | 105 | 1.240 |
Why?
|
| Treatment Refusal | 6 | 2015 | 33 | 1.200 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 7 | 2020 | 88 | 1.160 |
Why?
|
| Rotavirus Vaccines | 5 | 2020 | 52 | 1.150 |
Why?
|
| Patient Safety | 2 | 2020 | 39 | 1.150 |
Why?
|
| Models, Statistical | 4 | 2014 | 178 | 1.130 |
Why?
|
| Colorado | 12 | 2024 | 164 | 1.100 |
Why?
|
| Patient Education as Topic | 4 | 2019 | 212 | 1.080 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 5 | 2016 | 93 | 1.060 |
Why?
|
| Incidence | 17 | 2022 | 1266 | 1.000 |
Why?
|
| Adolescent | 35 | 2021 | 3685 | 0.980 |
Why?
|
| Naloxone | 5 | 2020 | 19 | 0.960 |
Why?
|
| Vaccination Coverage | 6 | 2024 | 45 | 0.960 |
Why?
|
| Case-Control Studies | 20 | 2020 | 1120 | 0.930 |
Why?
|
| Adult | 36 | 2024 | 7678 | 0.930 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 7 | 2021 | 62 | 0.900 |
Why?
|
| Whooping Cough | 4 | 2013 | 66 | 0.900 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 65 | 0.890 |
Why?
|
| Risk Assessment | 11 | 2020 | 1101 | 0.830 |
Why?
|
| Statistics as Topic | 2 | 2013 | 64 | 0.830 |
Why?
|
| Narcotic Antagonists | 3 | 2020 | 16 | 0.820 |
Why?
|
| Measles | 2 | 2021 | 24 | 0.810 |
Why?
|
| Antigens | 2 | 2021 | 7 | 0.800 |
Why?
|
| Decision Making | 4 | 2019 | 183 | 0.800 |
Why?
|
| Safety | 4 | 2016 | 41 | 0.790 |
Why?
|
| Vaccines, Attenuated | 4 | 2020 | 45 | 0.780 |
Why?
|
| Bias | 3 | 2019 | 102 | 0.750 |
Why?
|
| Product Surveillance, Postmarketing | 7 | 2022 | 95 | 0.750 |
Why?
|
| Text Messaging | 1 | 2021 | 29 | 0.730 |
Why?
|
| Reminder Systems | 1 | 2021 | 80 | 0.710 |
Why?
|
| Pregnancy | 15 | 2024 | 1524 | 0.690 |
Why?
|
| Chickenpox Vaccine | 5 | 2021 | 91 | 0.690 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2020 | 107 | 0.680 |
Why?
|
| Communicable Diseases | 1 | 2020 | 15 | 0.680 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 4 | 2017 | 52 | 0.650 |
Why?
|
| Infant, Newborn | 14 | 2025 | 855 | 0.640 |
Why?
|
| Disease Outbreaks | 3 | 2015 | 36 | 0.630 |
Why?
|
| Naltrexone | 1 | 2018 | 17 | 0.620 |
Why?
|
| Pneumococcal Vaccines | 3 | 2020 | 66 | 0.620 |
Why?
|
| Infection | 1 | 2018 | 17 | 0.600 |
Why?
|
| Electronic Health Records | 5 | 2019 | 697 | 0.590 |
Why?
|
| Abortion, Spontaneous | 4 | 2021 | 47 | 0.580 |
Why?
|
| Patient Compliance | 2 | 2019 | 300 | 0.580 |
Why?
|
| Gastrointestinal Diseases | 2 | 2018 | 27 | 0.580 |
Why?
|
| Young Adult | 20 | 2024 | 2461 | 0.580 |
Why?
|
| Information Dissemination | 1 | 2017 | 51 | 0.570 |
Why?
|
| Professional-Family Relations | 2 | 2015 | 49 | 0.550 |
Why?
|
| Middle Aged | 22 | 2024 | 7988 | 0.530 |
Why?
|
| Odds Ratio | 5 | 2019 | 671 | 0.520 |
Why?
|
| Databases, Pharmaceutical | 1 | 2016 | 6 | 0.520 |
Why?
|
| Environmental Exposure | 2 | 2015 | 117 | 0.520 |
Why?
|
| Adjuvants, Immunologic | 1 | 2015 | 15 | 0.510 |
Why?
|
| Prescription Drug Diversion | 1 | 2015 | 3 | 0.490 |
Why?
|
| Hospitalization | 7 | 2020 | 808 | 0.480 |
Why?
|
| Housing | 1 | 2015 | 39 | 0.480 |
Why?
|
| Health Education | 1 | 2014 | 111 | 0.450 |
Why?
|
| Algorithms | 2 | 2014 | 239 | 0.450 |
Why?
|
| Biometry | 1 | 2014 | 13 | 0.450 |
Why?
|
| Managed Care Programs | 2 | 2013 | 325 | 0.450 |
Why?
|
| Selection Bias | 1 | 2013 | 19 | 0.450 |
Why?
|
| Sentinel Surveillance | 1 | 2013 | 12 | 0.450 |
Why?
|
| Trust | 1 | 2013 | 31 | 0.440 |
Why?
|
| Confidence Intervals | 5 | 2021 | 237 | 0.430 |
Why?
|
| Biostatistics | 1 | 2012 | 10 | 0.400 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2012 | 5 | 0.400 |
Why?
|
| Health Services | 1 | 2013 | 112 | 0.390 |
Why?
|
| Models, Theoretical | 4 | 2020 | 70 | 0.390 |
Why?
|
| Aged | 13 | 2024 | 6150 | 0.380 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 381 | 0.380 |
Why?
|
| Intussusception | 3 | 2014 | 16 | 0.380 |
Why?
|
| Public Health Surveillance | 3 | 2020 | 42 | 0.380 |
Why?
|
| Time Factors | 8 | 2013 | 1093 | 0.380 |
Why?
|
| Immunization | 4 | 2024 | 70 | 0.370 |
Why?
|
| Epidemiologic Research Design | 1 | 2010 | 18 | 0.360 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2010 | 13 | 0.360 |
Why?
|
| Logistic Models | 6 | 2020 | 927 | 0.360 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 710 | 0.360 |
Why?
|
| Pandemics | 5 | 2024 | 287 | 0.350 |
Why?
|
| Prescriptions | 2 | 2020 | 27 | 0.350 |
Why?
|
| Risk | 11 | 2021 | 517 | 0.350 |
Why?
|
| Focus Groups | 3 | 2015 | 147 | 0.340 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 132 | 0.340 |
Why?
|
| Chickenpox | 1 | 2010 | 35 | 0.330 |
Why?
|
| Qualitative Research | 4 | 2020 | 256 | 0.330 |
Why?
|
| Pertussis Vaccine | 1 | 2009 | 14 | 0.330 |
Why?
|
| Age Factors | 6 | 2020 | 918 | 0.320 |
Why?
|
| Mortality | 3 | 2021 | 118 | 0.320 |
Why?
|
| Computer Simulation | 4 | 2013 | 82 | 0.320 |
Why?
|
| Population Surveillance | 6 | 2013 | 264 | 0.310 |
Why?
|
| Thrombocytopenia | 2 | 2022 | 15 | 0.300 |
Why?
|
| Research Design | 4 | 2024 | 376 | 0.300 |
Why?
|
| Immunization Programs | 4 | 2022 | 65 | 0.290 |
Why?
|
| Epidemiologic Methods | 3 | 2019 | 81 | 0.280 |
Why?
|
| Alcoholism | 5 | 2012 | 348 | 0.280 |
Why?
|
| Chronic Pain | 2 | 2020 | 127 | 0.280 |
Why?
|
| Database Management Systems | 2 | 2020 | 14 | 0.270 |
Why?
|
| Risk Factors | 12 | 2020 | 3356 | 0.270 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 3 | 2016 | 32 | 0.270 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1330 | 0.260 |
Why?
|
| Heroin Dependence | 2 | 2020 | 6 | 0.240 |
Why?
|
| Health Services Research | 1 | 2006 | 231 | 0.240 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 568 | 0.230 |
Why?
|
| Immunity, Humoral | 1 | 2024 | 4 | 0.230 |
Why?
|
| Alcohol Drinking | 3 | 2002 | 373 | 0.230 |
Why?
|
| Seasons | 4 | 2024 | 105 | 0.230 |
Why?
|
| RNA, Viral | 1 | 2024 | 64 | 0.230 |
Why?
|
| World Health Organization | 3 | 2002 | 14 | 0.230 |
Why?
|
| Health Behavior | 2 | 2019 | 360 | 0.230 |
Why?
|
| Stillbirth | 2 | 2021 | 29 | 0.230 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 354 | 0.230 |
Why?
|
| Seizures | 2 | 2014 | 29 | 0.230 |
Why?
|
| Premature Birth | 2 | 2024 | 137 | 0.210 |
Why?
|
| Gestational Age | 2 | 2021 | 111 | 0.210 |
Why?
|
| Substance-Related Disorders | 3 | 2020 | 434 | 0.210 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 1321 | 0.210 |
Why?
|
| Monkeypox | 1 | 2022 | 1 | 0.210 |
Why?
|
| Smallpox Vaccine | 1 | 2022 | 6 | 0.210 |
Why?
|
| Drug Prescriptions | 2 | 2015 | 151 | 0.210 |
Why?
|
| Morphine Derivatives | 1 | 2022 | 4 | 0.210 |
Why?
|
| Eczema | 1 | 2022 | 7 | 0.210 |
Why?
|
| Pericarditis | 1 | 2022 | 11 | 0.200 |
Why?
|
| Myocarditis | 1 | 2022 | 14 | 0.200 |
Why?
|
| Data Interpretation, Statistical | 2 | 2021 | 77 | 0.200 |
Why?
|
| Cataplexy | 1 | 2022 | 5 | 0.200 |
Why?
|
| Narcolepsy | 1 | 2022 | 6 | 0.200 |
Why?
|
| Bell Palsy | 1 | 2022 | 14 | 0.200 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2022 | 15 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2014 | 315 | 0.200 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2021 | 331 | 0.200 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2014 | 23 | 0.200 |
Why?
|
| Anemia, Sickle Cell | 2 | 2011 | 9 | 0.190 |
Why?
|
| Maternal Age | 1 | 2021 | 77 | 0.190 |
Why?
|
| Medical Informatics | 2 | 2019 | 38 | 0.190 |
Why?
|
| Sex Factors | 3 | 2021 | 644 | 0.190 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1213 | 0.190 |
Why?
|
| HIV Infections | 2 | 2024 | 696 | 0.180 |
Why?
|
| Heroin | 1 | 2020 | 5 | 0.180 |
Why?
|
| Haemophilus Vaccines | 1 | 2020 | 17 | 0.180 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 304 | 0.180 |
Why?
|
| Telemedicine | 1 | 2024 | 186 | 0.180 |
Why?
|
| Withholding Treatment | 1 | 2020 | 26 | 0.180 |
Why?
|
| Motivation | 1 | 2021 | 131 | 0.170 |
Why?
|
| London | 1 | 2020 | 6 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 37 | 0.170 |
Why?
|
| Congresses as Topic | 1 | 2020 | 13 | 0.170 |
Why?
|
| Pilot Projects | 1 | 2020 | 218 | 0.170 |
Why?
|
| Bacterial Vaccines | 2 | 2023 | 9 | 0.170 |
Why?
|
| Insurance, Health | 1 | 2021 | 183 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.170 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 56 | 0.170 |
Why?
|
| Papillomavirus Vaccines | 1 | 2021 | 113 | 0.160 |
Why?
|
| California | 2 | 2024 | 2326 | 0.160 |
Why?
|
| Pregnant Women | 1 | 2020 | 45 | 0.160 |
Why?
|
| Vaccination Refusal | 1 | 2019 | 9 | 0.160 |
Why?
|
| Asthma | 1 | 2022 | 385 | 0.160 |
Why?
|
| Parenting | 1 | 2019 | 29 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 139 | 0.160 |
Why?
|
| Cause of Death | 3 | 2018 | 181 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2021 | 535 | 0.160 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 6 | 0.160 |
Why?
|
| Croup | 1 | 2018 | 4 | 0.150 |
Why?
|
| Otitis Media | 1 | 2018 | 18 | 0.150 |
Why?
|
| Infant Mortality | 1 | 2018 | 20 | 0.150 |
Why?
|
| Attitude to Health | 1 | 2019 | 164 | 0.150 |
Why?
|
| Chronic Disease | 2 | 2013 | 428 | 0.150 |
Why?
|
| Analysis of Variance | 4 | 2008 | 159 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 50 | 0.140 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2017 | 22 | 0.140 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 213 | 0.140 |
Why?
|
| Pneumonia | 1 | 2017 | 51 | 0.140 |
Why?
|
| Poisson Distribution | 3 | 2014 | 88 | 0.140 |
Why?
|
| Measles Vaccine | 1 | 2017 | 17 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2017 | 105 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 53 | 0.140 |
Why?
|
| Fever | 1 | 2017 | 55 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2017 | 90 | 0.140 |
Why?
|
| Acute Disease | 2 | 2008 | 142 | 0.130 |
Why?
|
| Socioeconomic Factors | 5 | 2019 | 630 | 0.130 |
Why?
|
| Immunization, Secondary | 3 | 2014 | 57 | 0.130 |
Why?
|
| Sex Distribution | 3 | 2017 | 190 | 0.130 |
Why?
|
| Ambulatory Care | 2 | 2018 | 247 | 0.130 |
Why?
|
| Age Distribution | 3 | 2017 | 246 | 0.120 |
Why?
|
| General Practice | 1 | 2015 | 6 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2015 | 99 | 0.120 |
Why?
|
| Seizures, Febrile | 2 | 2013 | 42 | 0.120 |
Why?
|
| User-Computer Interface | 1 | 2014 | 26 | 0.120 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 72 | 0.120 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2013 | 15 | 0.120 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 1923 | 0.120 |
Why?
|
| Program Development | 1 | 2014 | 69 | 0.120 |
Why?
|
| Community Health Services | 1 | 2015 | 83 | 0.120 |
Why?
|
| Prisoners | 1 | 2015 | 54 | 0.120 |
Why?
|
| Needle Sharing | 2 | 2005 | 2 | 0.110 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2014 | 21 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 186 | 0.110 |
Why?
|
| Viral Vaccines | 1 | 2014 | 12 | 0.110 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2005 | 33 | 0.110 |
Why?
|
| Communication | 1 | 2015 | 194 | 0.110 |
Why?
|
| Mass Vaccination | 1 | 2013 | 22 | 0.110 |
Why?
|
| Prehypertension | 1 | 2013 | 22 | 0.110 |
Why?
|
| Hepatitis C | 2 | 2005 | 65 | 0.110 |
Why?
|
| Drug Utilization | 1 | 2013 | 128 | 0.110 |
Why?
|
| Genes, MHC Class II | 1 | 2012 | 2 | 0.110 |
Why?
|
| Primary Health Care | 2 | 2016 | 769 | 0.110 |
Why?
|
| Diphtheria | 1 | 2012 | 13 | 0.100 |
Why?
|
| Tetanus | 1 | 2012 | 17 | 0.100 |
Why?
|
| Prescription Drugs | 1 | 2013 | 31 | 0.100 |
Why?
|
| Adenylyl Cyclases | 2 | 2002 | 2 | 0.100 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2012 | 102 | 0.100 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 66 | 0.100 |
Why?
|
| Prisons | 1 | 2012 | 29 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2012 | 95 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2013 | 302 | 0.090 |
Why?
|
| Community Health Centers | 1 | 2012 | 64 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 169 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2012 | 157 | 0.090 |
Why?
|
| Autistic Disorder | 1 | 2011 | 100 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2008 | 86 | 0.090 |
Why?
|
| Anemia, Hemolytic | 1 | 2009 | 2 | 0.080 |
Why?
|
| Linear Models | 2 | 2008 | 231 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 455 | 0.080 |
Why?
|
| Hepatitis B Vaccines | 1 | 2009 | 43 | 0.080 |
Why?
|
| Registries | 2 | 2008 | 472 | 0.080 |
Why?
|
| Brain Ischemia | 1 | 2009 | 37 | 0.080 |
Why?
|
| Hypertension | 1 | 2013 | 504 | 0.080 |
Why?
|
| Drug Evaluation | 1 | 2008 | 6 | 0.080 |
Why?
|
| Health Surveys | 1 | 2009 | 260 | 0.080 |
Why?
|
| Splenectomy | 1 | 2008 | 2 | 0.080 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2008 | 2 | 0.080 |
Why?
|
| Platelet Count | 1 | 2008 | 9 | 0.080 |
Why?
|
| Communicable Disease Control | 1 | 2008 | 18 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2014 | 1279 | 0.070 |
Why?
|
| Mass Screening | 1 | 2013 | 677 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2008 | 215 | 0.070 |
Why?
|
| Regression Analysis | 4 | 2015 | 300 | 0.070 |
Why?
|
| Disease Progression | 1 | 2008 | 264 | 0.070 |
Why?
|
| Prognosis | 1 | 2008 | 609 | 0.070 |
Why?
|
| Stroke | 1 | 2009 | 315 | 0.060 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2006 | 86 | 0.060 |
Why?
|
| Hepatitis B | 1 | 2005 | 42 | 0.060 |
Why?
|
| Health Personnel | 2 | 2015 | 125 | 0.060 |
Why?
|
| Family Characteristics | 1 | 2023 | 55 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 156 | 0.050 |
Why?
|
| Cooperative Behavior | 2 | 2014 | 91 | 0.050 |
Why?
|
| Vaccines, Combined | 2 | 2014 | 80 | 0.050 |
Why?
|
| Monoamine Oxidase | 1 | 2002 | 1 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2002 | 2 | 0.050 |
Why?
|
| Prevalence | 2 | 2021 | 886 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2002 | 25 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2022 | 72 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 154 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 34 | 0.050 |
Why?
|
| Body Water | 1 | 2001 | 3 | 0.050 |
Why?
|
| Transferrin | 1 | 2001 | 5 | 0.050 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2001 | 1 | 0.050 |
Why?
|
| Radon | 1 | 2001 | 3 | 0.050 |
Why?
|
| Policy | 1 | 2021 | 18 | 0.050 |
Why?
|
| Bacterial Capsules | 1 | 2020 | 5 | 0.050 |
Why?
|
| Health Facilities | 1 | 2020 | 17 | 0.040 |
Why?
|
| Mutation | 1 | 2001 | 130 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 146 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 24 | 0.040 |
Why?
|
| Smoking | 1 | 2002 | 483 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2021 | 302 | 0.040 |
Why?
|
| Psychometrics | 1 | 2019 | 121 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 25 | 0.040 |
Why?
|
| Ethnic Groups | 1 | 2021 | 485 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 21 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 85 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 44 | 0.040 |
Why?
|
| Outpatients | 1 | 2018 | 110 | 0.030 |
Why?
|
| Family Health | 1 | 2017 | 44 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2001 | 964 | 0.030 |
Why?
|
| Biomarkers | 3 | 2002 | 303 | 0.030 |
Why?
|
| Neoplasms | 1 | 2001 | 444 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 597 | 0.030 |
Why?
|
| Contraindications | 1 | 2014 | 14 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 46 | 0.030 |
Why?
|
| Anaphylaxis | 1 | 2013 | 15 | 0.030 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2013 | 18 | 0.030 |
Why?
|
| Fetal Mortality | 1 | 2013 | 2 | 0.030 |
Why?
|
| Fetal Death | 1 | 2013 | 9 | 0.030 |
Why?
|
| Vaccines, Acellular | 1 | 2012 | 11 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 2013 | 59 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2013 | 35 | 0.030 |
Why?
|
| Off-Label Use | 1 | 2012 | 14 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 292 | 0.030 |
Why?
|
| Hepatitis A Vaccines | 1 | 2012 | 14 | 0.020 |
Why?
|
| Rotavirus Infections | 1 | 2012 | 31 | 0.020 |
Why?
|
| Monitoring, Immunologic | 1 | 2011 | 4 | 0.020 |
Why?
|
| Safety Management | 1 | 2011 | 14 | 0.020 |
Why?
|
| Family | 1 | 2012 | 111 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 375 | 0.020 |
Why?
|
| Mental Health | 1 | 2012 | 166 | 0.020 |
Why?
|
| Suicide | 1 | 2012 | 124 | 0.020 |
Why?
|
| Social Support | 1 | 2012 | 206 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 197 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2012 | 368 | 0.020 |
Why?
|
| Syringes | 1 | 2005 | 1 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2005 | 5 | 0.020 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2005 | 4 | 0.020 |
Why?
|
| Social Identification | 1 | 2005 | 7 | 0.020 |
Why?
|
| Methamphetamine | 1 | 2005 | 3 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 46 | 0.010 |
Why?
|
| Medical Record Linkage | 1 | 2004 | 38 | 0.010 |
Why?
|
| Social Environment | 1 | 2005 | 88 | 0.010 |
Why?
|
| Equipment Contamination | 1 | 2003 | 1 | 0.010 |
Why?
|
| Illinois | 1 | 2003 | 8 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 417 | 0.010 |
Why?
|
| Affinity Labels | 1 | 2002 | 1 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 6 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 9 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 50 | 0.010 |
Why?
|
| Marijuana Abuse | 1 | 2002 | 40 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2001 | 3 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 2001 | 13 | 0.010 |
Why?
|
| Multifactorial Inheritance | 1 | 2001 | 20 | 0.010 |
Why?
|
| Causality | 1 | 2001 | 40 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 719 | 0.010 |
Why?
|